maxen schreef op 28 maart 2019 22:02:
Wow!
Three venous thrombotic events were observed (two in the placebo group, one in the filgotinib 200 mg group), and there were four adjudicated major adverse cardiovascular events, two in the placebo, one in the adalimumab and one in the filgotinib 100 mg groups.
Dus slechts een DVT bij filgotinib! Bevestiging Darwin trials! Veruit het laagste van alle JAKs!